董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Arnold A. Pinkston | 男 | Independent Director | 66 | 17.88万美元 | 未持股 | 2025-08-04 |
| Melinda Litherland | 女 | Independent Director | 67 | 19.50万美元 | 未持股 | 2025-08-04 |
| Allison Schwartz | 女 | Director and Vice President, Global Supply Chain Clinical Diagnostics Group Operations | 44 | 未披露 | 2.05 | 2025-08-04 |
| Gregory K. Hinckley | 男 | Lead Independent Director | 78 | 19.93万美元 | 0.05 | 2025-08-04 |
| Jeffrey L. Edwards | 男 | Independent Director | 64 | 19.00万美元 | 未持股 | 2025-08-04 |
| Norman Schwartz | 男 | Chairman of the Board and Chief Executive Officer | 75 | 746.39万美元 | 83.76 | 2025-08-04 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Roop K. Lakkaraju | 男 | Principal Accounting Officer, Executive Vice President and Chief Financial Officer | 54 | 未披露 | 未持股 | 2025-08-04 |
| Allison Schwartz | 女 | Director and Vice President, Global Supply Chain Clinical Diagnostics Group Operations | 44 | 未披露 | 2.05 | 2025-08-04 |
| Colleen Corey | 女 | Executive Vice President, Global Human Resources | 63 | 未披露 | 未持股 | 2025-08-04 |
| Sedat Evran | 男 | Executive Vice President, Global Supply Chain | 53 | 未披露 | 未持股 | 2025-08-04 |
| Jonathan P. DiVincenzo | 男 | President and Chief Operating Officer | 59 | 未披露 | 未持股 | 2025-08-04 |
| James J. Barry | 男 | Executive Vice President and President, Life Science Group | -- | 未披露 | 未持股 | 2025-08-04 |
| Rajat Mehta | 男 | Executive Vice President, Global Commercial Operations | -- | 未披露 | 未持股 | 2025-08-04 |
| Eva Anette Engelhardt | -- | Executive Vice President and President, Clinical Diagnostics Group | -- | 未披露 | 未持股 | 2025-08-04 |
| Courtney Camp Enloe | -- | Executive Vice President, General Counsel and Secretary | -- | 未披露 | 未持股 | 2025-08-04 |
| Norman Schwartz | 男 | Chairman of the Board and Chief Executive Officer | 75 | 746.39万美元 | 83.76 | 2025-08-04 |
董事简历
中英对照 | 中文 | 英文- Arnold A. Pinkston
-
Arnold A. Pinkston，2016年1月以来，他担任公司的董事。2016年1月以来，他担任可持续发展会计准则委员会董事。从2011年10月到2015年3月，他担任Allergan, Inc.的执行副总裁兼法律总顾问。从2005年11月到2011年5月，他担任Beckman Coulter的高级副总裁、总法律顾问和秘书。从1994年3月至2005年11月，他担任Eli Lilly和公司的副总裁。从1999年1月至2001年11月和2003年2月到2005年11月，他担任Eli Lilly和公司的副总法律顾问。从2008年到2015年，他担任OneOC（一个非盈利的公司）的董事。从2013年到2014年，他担任董事长。从2003年到2005，他担任St Vincent Health hospital system的董事。从2002年到2005年，他担任Indianapolis Local Public Improvement Bond Bank的董事。从2003年到2005年，他担任Innocentive, Inc.（众包创新解决方案公司）的董事。从1998年到1999年，他担任Southwest Autism Research Center的董事。从1996年到1998年，他担任Valley Big Brothers and Big Sisters（非营利公司）的董事。从1993年到1995年，他担任Bay Area Urban League（非营利公司）的董事。他在耶鲁大学获得地球物理专业的学士学位，在耶鲁法学院获得法学博士学位。
Arnold A. Pinkston,is currently the Corporate Vice President, General Counsel of Edwards Lifesciences Corporation, a global leader in patient-focused medical innovations for heart disease, as well as critical care and surgical monitoring. Prior to joining Edwards in July 2019, he served as the Chief Legal Officer and Corporate Secretary of CoreLogic, Inc., a leading global property information, analytics and data-enabled solutions provider from January 2018 until June 2019. From 2011 until March 2015, he served as Executive Vice President and General Counsel for Allergan, Inc., a multi-specialty health care company. From 2005 until 2011, Mr. Pinkston served as Senior Vice President, General Counsel and Secretary for Beckman Coulter, Inc., a health care diagnostics and life sciences company. From 1994 until 2005, he held various positions at Eli Lilly and Company, a global pharmaceutical company, including Vice President and Deputy General Counsel. Additionally, Mr. Pinkston was formerly a director of Janus Capital Group, a publicly owned investment firm. Mr. Pinkston has over 25 years of experience at successful public companies. - Arnold A. Pinkston，2016年1月以来，他担任公司的董事。2016年1月以来，他担任可持续发展会计准则委员会董事。从2011年10月到2015年3月，他担任Allergan, Inc.的执行副总裁兼法律总顾问。从2005年11月到2011年5月，他担任Beckman Coulter的高级副总裁、总法律顾问和秘书。从1994年3月至2005年11月，他担任Eli Lilly和公司的副总裁。从1999年1月至2001年11月和2003年2月到2005年11月，他担任Eli Lilly和公司的副总法律顾问。从2008年到2015年，他担任OneOC（一个非盈利的公司）的董事。从2013年到2014年，他担任董事长。从2003年到2005，他担任St Vincent Health hospital system的董事。从2002年到2005年，他担任Indianapolis Local Public Improvement Bond Bank的董事。从2003年到2005年，他担任Innocentive, Inc.（众包创新解决方案公司）的董事。从1998年到1999年，他担任Southwest Autism Research Center的董事。从1996年到1998年，他担任Valley Big Brothers and Big Sisters（非营利公司）的董事。从1993年到1995年，他担任Bay Area Urban League（非营利公司）的董事。他在耶鲁大学获得地球物理专业的学士学位，在耶鲁法学院获得法学博士学位。
- Arnold A. Pinkston,is currently the Corporate Vice President, General Counsel of Edwards Lifesciences Corporation, a global leader in patient-focused medical innovations for heart disease, as well as critical care and surgical monitoring. Prior to joining Edwards in July 2019, he served as the Chief Legal Officer and Corporate Secretary of CoreLogic, Inc., a leading global property information, analytics and data-enabled solutions provider from January 2018 until June 2019. From 2011 until March 2015, he served as Executive Vice President and General Counsel for Allergan, Inc., a multi-specialty health care company. From 2005 until 2011, Mr. Pinkston served as Senior Vice President, General Counsel and Secretary for Beckman Coulter, Inc., a health care diagnostics and life sciences company. From 1994 until 2005, he held various positions at Eli Lilly and Company, a global pharmaceutical company, including Vice President and Deputy General Counsel. Additionally, Mr. Pinkston was formerly a director of Janus Capital Group, a publicly owned investment firm. Mr. Pinkston has over 25 years of experience at successful public companies.
- Melinda Litherland
-
Melinda Litherland，她于2015年退休，担任Deloitte&Touche LLP的合伙人（1981年以来）。她是一名注册会计师，在生命科学和技术公司的审计和咨询职位上拥有34年的工作经验。Litherland女士是CPAS AICPA美国研究所的成员，此前曾在Ronald McDonald House Charities Bay Area董事会任职12年，包括在财务委员会任职。
Melinda Litherland,retired in 2015 as a Partner at Deloitte & Touche LLP, where she worked since 1981. She is a certified public accountant with 34 years of experience working with life science and technology companies in both audit and consulting capacities. Ms. Litherland currently serves on the Board of Directors and as Audit Committee chair of Rapid Micro Biosystems, Inc., a publicly traded life sciences technology company. Ms. Litherland is a member of the American Institute of CPAs (AICPA) and previously served for 12 years on the Board of Directors of Ronald McDonald House Charities Bay Area, including serving on the Finance Committee. - Melinda Litherland，她于2015年退休，担任Deloitte&Touche LLP的合伙人（1981年以来）。她是一名注册会计师，在生命科学和技术公司的审计和咨询职位上拥有34年的工作经验。Litherland女士是CPAS AICPA美国研究所的成员，此前曾在Ronald McDonald House Charities Bay Area董事会任职12年，包括在财务委员会任职。
- Melinda Litherland,retired in 2015 as a Partner at Deloitte & Touche LLP, where she worked since 1981. She is a certified public accountant with 34 years of experience working with life science and technology companies in both audit and consulting capacities. Ms. Litherland currently serves on the Board of Directors and as Audit Committee chair of Rapid Micro Biosystems, Inc., a publicly traded life sciences technology company. Ms. Litherland is a member of the American Institute of CPAs (AICPA) and previously served for 12 years on the Board of Directors of Ronald McDonald House Charities Bay Area, including serving on the Finance Committee.
- Allison Schwartz
-
Allison Schwartz，现任Bio-Rad Laboratories（加拿大）有限公司（子公司）商务总监，于2023年1月被任命担任该职务。在此之前，Schwartz女士于2021年7月至2023年1月担任Bio-Rad Laboratories（加拿大）有限公司的营销总监，之前于2016年至2021年担任Bio-Rad Laboratories的商务服务总监，负责全球数字营销、电子商务、客户体验和定价。自2005年加入Bio-Rad以来，她一直在国内外品牌开发、产品营销和物流管理方面担任职务。
Allison Schwartz,is currently the Commercial Director at Bio-Rad Laboratories (Canada) Limited (a subsidiary of the Company), a role to which she was appointed in January 2023. Prior to this assignment, Ms. Schwartz served as the Marketing Director at Bio-Rad Laboratories (Canada) Limited from July 2021 to January 2023, and previously as the Commercial Services Director at the Company from 2016 until 2021, with accountabilities in these roles spanning global digital marketing, eCommerce, customer experience, and pricing. Since joining Bio-Rad in 2005, she has held positions in domestic and international brand development, product marketing and logistics management. - Allison Schwartz，现任Bio-Rad Laboratories（加拿大）有限公司（子公司）商务总监，于2023年1月被任命担任该职务。在此之前，Schwartz女士于2021年7月至2023年1月担任Bio-Rad Laboratories（加拿大）有限公司的营销总监，之前于2016年至2021年担任Bio-Rad Laboratories的商务服务总监，负责全球数字营销、电子商务、客户体验和定价。自2005年加入Bio-Rad以来，她一直在国内外品牌开发、产品营销和物流管理方面担任职务。
- Allison Schwartz,is currently the Commercial Director at Bio-Rad Laboratories (Canada) Limited (a subsidiary of the Company), a role to which she was appointed in January 2023. Prior to this assignment, Ms. Schwartz served as the Marketing Director at Bio-Rad Laboratories (Canada) Limited from July 2021 to January 2023, and previously as the Commercial Services Director at the Company from 2016 until 2021, with accountabilities in these roles spanning global digital marketing, eCommerce, customer experience, and pricing. Since joining Bio-Rad in 2005, she has held positions in domestic and international brand development, product marketing and logistics management.
- Gregory K. Hinckley
-
Gregory K. Hinckley在Mentor Graphics工作了20年后，于2017年7月从Mentor Graphics Corporation退休，Mentor Graphics Corporation是电子设计计算机自动化软件的领导者。1999年至2017年7月，他担任Mentor Graphics总裁。从1997年到1999年，他担任Mentor Graphics的执行副总裁、首席运营和财务官。在1997年加入Mentor Graphics之前，Hinckley先生曾在VLSI Technology，Inc.担任首席财务官，VLSI Technology，Inc.是一家上市的综合半导体器件公司，1992-1997年在Crowley Maritime Corporation任职，1989-1991年在Bio-Rad任职，1983-1989年在Bio-Rad Laboratories, Inc.任职。他目前担任SI-BONE, Inc.的董事和审计委员会成员，SI-BONE公司是一家上市的骨科器械公司。Hinckley先生还担任Claremont McKenna College和Portland State University的董事，并担任校董会主席。Hinckley先生曾担任其他几家上市公司的董事，包括自动识别和数据收集AIDC解决方案的上市供应商Intermec，Inc.，高级计算机服务器系统和子系统的上市供应商Super Micro，以及外包半导体互连服务的领先供应商Amkor Technology。Hinckley拥有40多年的上市公司经验。
Gregory K. Hinckley,retired from Mentor Graphics Corporation, a leader in computer automated software for electronics design, in July 2017 after 20 years at Mentor Graphics. From 1999 to July 2017, he served as President of Mentor Graphics. From 1997 to 1999, he served as Mentor Graphics' Executive Vice President, Chief Operating and Financial Officer. Prior to joining Mentor Graphics in 1997, Mr. Hinckley served as Chief Financial Officer for VLSI Technology, Inc., a publicly traded integrated semiconductor device company, from 1992-1997, for Crowley Maritime Corporation from 1989-1991 and for Bio-Rad from 1983-1989. He currently serves as a director and on the Audit Committee of SI-BONE, Inc., a publicly traded orthopedic device company, and on the Board of Portland State University. Mr. Hinckley previously served as a director for several other publicly traded companies including Intermec, Inc., a publicly traded provider of automated identification and data collection (AIDC) solutions, Super Micro, a publicly traded provider of advanced computer server systems and subsystems, and Amkor Technology, a leading supplier of outsourced semiconductor interconnect services. Mr. Hinckley has over 40 years of public company experience. - Gregory K. Hinckley在Mentor Graphics工作了20年后，于2017年7月从Mentor Graphics Corporation退休，Mentor Graphics Corporation是电子设计计算机自动化软件的领导者。1999年至2017年7月，他担任Mentor Graphics总裁。从1997年到1999年，他担任Mentor Graphics的执行副总裁、首席运营和财务官。在1997年加入Mentor Graphics之前，Hinckley先生曾在VLSI Technology，Inc.担任首席财务官，VLSI Technology，Inc.是一家上市的综合半导体器件公司，1992-1997年在Crowley Maritime Corporation任职，1989-1991年在Bio-Rad任职，1983-1989年在Bio-Rad Laboratories, Inc.任职。他目前担任SI-BONE, Inc.的董事和审计委员会成员，SI-BONE公司是一家上市的骨科器械公司。Hinckley先生还担任Claremont McKenna College和Portland State University的董事，并担任校董会主席。Hinckley先生曾担任其他几家上市公司的董事，包括自动识别和数据收集AIDC解决方案的上市供应商Intermec，Inc.，高级计算机服务器系统和子系统的上市供应商Super Micro，以及外包半导体互连服务的领先供应商Amkor Technology。Hinckley拥有40多年的上市公司经验。
- Gregory K. Hinckley,retired from Mentor Graphics Corporation, a leader in computer automated software for electronics design, in July 2017 after 20 years at Mentor Graphics. From 1999 to July 2017, he served as President of Mentor Graphics. From 1997 to 1999, he served as Mentor Graphics' Executive Vice President, Chief Operating and Financial Officer. Prior to joining Mentor Graphics in 1997, Mr. Hinckley served as Chief Financial Officer for VLSI Technology, Inc., a publicly traded integrated semiconductor device company, from 1992-1997, for Crowley Maritime Corporation from 1989-1991 and for Bio-Rad from 1983-1989. He currently serves as a director and on the Audit Committee of SI-BONE, Inc., a publicly traded orthopedic device company, and on the Board of Portland State University. Mr. Hinckley previously served as a director for several other publicly traded companies including Intermec, Inc., a publicly traded provider of automated identification and data collection (AIDC) solutions, Super Micro, a publicly traded provider of advanced computer server systems and subsystems, and Amkor Technology, a leading supplier of outsourced semiconductor interconnect services. Mr. Hinckley has over 40 years of public company experience.
- Jeffrey L. Edwards
-
Jeffrey L. Edwards，在Allergan工作近22年后于2015年2月从Allergan, Inc.（多专业医疗保健公司）退休。从2005年9月到2014年8月，他担任Allergan的财务和业务发展执行副总裁、首席财务官。从2003年到2005年，他担任Allergan公司的企业发展副总裁，此前曾担任财务、税务和投资者关系高级副总裁。在加入Allergan之前，他曾任职Banque Paribas和Security Pacific National Bank，在那里他担任信贷和业务发展职能部门的各种高级职位。他目前担任FibroGen, Inc.（上市的生物制药公司）的董事会和审计委员会主席；Clearside Biomedical, Inc.（上市的发展阶段制药公司）的董事会、提名和公司治理委员会和审计委员会成员；他是Lifecore Biomedical, Inc.（一家上市公司，是医疗设备和制药行业内完全集成的合同开发和制造组织（CDMO））的董事会成员、提名和治理委员会成员以及审计委员会主席。他拥有超过30年的上市公司经验。
Jeffrey L. Edwards,retired from Allergan, Inc., a multi-specialty health care company, in February 2015 after nearly 22 years at Allergan. From September 2005 to August 2014, he served as Executive Vice President, Finance and Business Development, Chief Financial Officer at Allergan. From 2003 to 2005 he served as Allergan's Corporate Vice President, Corporate Development and previously served as Senior Vice President, Treasury, Tax and Investor Relations. Prior to joining Allergan, Mr. Edwards was with Banque Paribas and Security Pacific National Bank, where he held various senior-level positions in the credit and business development functions. Mr. Edwards currently serves on the Board of Directors and as Audit Committee chair of FibroGen, Inc., a publicly traded biopharmaceutical company; on the Board of Directors, the Nominating and Corporate Governance Committee and the Audit Committee of Clearside Biomedical, Inc., a publicly traded development stage pharmaceutical company; and on the Board of Directors, on the Nominating and Governance Committee and as the Audit Committee Chair of Lifecore Biomedical, Inc., a publicly traded company which is a fully integrated Contract Development and Manufacturing Organization (CDMO) within the medical device and pharmaceuticals sectors. Mr. Edwards has over 30 years of public company experience. - Jeffrey L. Edwards，在Allergan工作近22年后于2015年2月从Allergan, Inc.（多专业医疗保健公司）退休。从2005年9月到2014年8月，他担任Allergan的财务和业务发展执行副总裁、首席财务官。从2003年到2005年，他担任Allergan公司的企业发展副总裁，此前曾担任财务、税务和投资者关系高级副总裁。在加入Allergan之前，他曾任职Banque Paribas和Security Pacific National Bank，在那里他担任信贷和业务发展职能部门的各种高级职位。他目前担任FibroGen, Inc.（上市的生物制药公司）的董事会和审计委员会主席；Clearside Biomedical, Inc.（上市的发展阶段制药公司）的董事会、提名和公司治理委员会和审计委员会成员；他是Lifecore Biomedical, Inc.（一家上市公司，是医疗设备和制药行业内完全集成的合同开发和制造组织（CDMO））的董事会成员、提名和治理委员会成员以及审计委员会主席。他拥有超过30年的上市公司经验。
- Jeffrey L. Edwards,retired from Allergan, Inc., a multi-specialty health care company, in February 2015 after nearly 22 years at Allergan. From September 2005 to August 2014, he served as Executive Vice President, Finance and Business Development, Chief Financial Officer at Allergan. From 2003 to 2005 he served as Allergan's Corporate Vice President, Corporate Development and previously served as Senior Vice President, Treasury, Tax and Investor Relations. Prior to joining Allergan, Mr. Edwards was with Banque Paribas and Security Pacific National Bank, where he held various senior-level positions in the credit and business development functions. Mr. Edwards currently serves on the Board of Directors and as Audit Committee chair of FibroGen, Inc., a publicly traded biopharmaceutical company; on the Board of Directors, the Nominating and Corporate Governance Committee and the Audit Committee of Clearside Biomedical, Inc., a publicly traded development stage pharmaceutical company; and on the Board of Directors, on the Nominating and Governance Committee and as the Audit Committee Chair of Lifecore Biomedical, Inc., a publicly traded company which is a fully integrated Contract Development and Manufacturing Organization (CDMO) within the medical device and pharmaceuticals sectors. Mr. Edwards has over 30 years of public company experience.
- Norman Schwartz
-
Norman Schwartz，2003年开始担任Bio-Rad Laboratories, Inc.总裁兼首席执行官，2012年成为董事会主席。1989年到2002年，他是Bio-Rad Laboratories, Inc.副总裁，1997年到2002年，他是Life Science集团经理。1993年到1997年，他是Clinical Diagnostics公司团队经理。
Norman Schwartz,has been Bio-Rad Laboratories, Inc. President and Chief Executive Officer since 2003 and Bio-Rad Laboratories, Inc. Chairman of the Board since 2012. He was Bio-Rad Laboratories, Inc. Vice President from 1989 to 2002, Bio-Rad Laboratories, Inc. Group Manager, Life Science, from 1997 to 2002 and Bio-Rad Laboratories, Inc. Group Manager, Clinical Diagnostics, from 1993 to 1997. - Norman Schwartz，2003年开始担任Bio-Rad Laboratories, Inc.总裁兼首席执行官，2012年成为董事会主席。1989年到2002年，他是Bio-Rad Laboratories, Inc.副总裁，1997年到2002年，他是Life Science集团经理。1993年到1997年，他是Clinical Diagnostics公司团队经理。
- Norman Schwartz,has been Bio-Rad Laboratories, Inc. President and Chief Executive Officer since 2003 and Bio-Rad Laboratories, Inc. Chairman of the Board since 2012. He was Bio-Rad Laboratories, Inc. Vice President from 1989 to 2002, Bio-Rad Laboratories, Inc. Group Manager, Life Science, from 1997 to 2002 and Bio-Rad Laboratories, Inc. Group Manager, Clinical Diagnostics, from 1993 to 1997.
高管简历
中英对照 | 中文 | 英文- Roop K. Lakkaraju
Roop K. Lakkaraju自2018年1月起担任执行副总裁、首席财务官。2017年2月至2018年1月，他在Maana，Inc.担任首席财务官，该公司是一家企业软件公司，率先推出了人工智能驱动的知识平台。2013年10月至2017年2月，他担任在线赞助 NASDAQ：SPRT的首席运营官和首席财务官，该公司是一家技术支持的基于云的软件和服务提供商。2011年7月至2013年10月，他担任Quantros，Inc.的首席财务官，Quantros，Inc.是一家基于企业SaaS的解决方案和信息服务提供商，可提升医疗保健的质量和安全绩效。在此之前，他曾在2Wire、Solectron Corporation（NYSE：SLR）和安科投资（NYSE：SFE）担任执行财务和运营职务。他的职业生涯始于1993年，在Grant Thornton担任审计员，之后加入了普华永道会计师事务所的审计和商业咨询服务部门。Lakkaraju先生拥有圣何塞州立大学工商管理学士学位。
Roop K. Lakkaraju has been Executive Vice President, Chief Financial Officer since January 2018. From February 2017 to January 2018 he served as Chief Financial Officer of Maana, Inc., an enterprise software company that has pioneered an Artificial Intelligence-driven knowledge platform. From October 2013 to February 2017 he served as Chief Operating Officer and Chief Financial Officer of Support.com NASDAQ:SPRT, a provider of cloud-based software and services for technology support. From July 2011 to October 2013 he was Chief Financial Officer of Quantros, Inc., a provider of enterprise SaaS-based solutions and information services that advance healthcare quality and safety performance. Prior to that he held executive financial and operational roles at 2Wire, Solectron Corporation (NYSE:SLR), and Safeguard Scientifics (NYSE:SFE). He began his career in 1993 as an auditor with Grant Thornton before joining PricewaterhouseCoopers in their Audit and Business Advisory Services. Mr. Lakkaraju holds a B.S. in Business Administration from San Jose State University.- Roop K. Lakkaraju自2018年1月起担任执行副总裁、首席财务官。2017年2月至2018年1月，他在Maana，Inc.担任首席财务官，该公司是一家企业软件公司，率先推出了人工智能驱动的知识平台。2013年10月至2017年2月，他担任在线赞助 NASDAQ：SPRT的首席运营官和首席财务官，该公司是一家技术支持的基于云的软件和服务提供商。2011年7月至2013年10月，他担任Quantros，Inc.的首席财务官，Quantros，Inc.是一家基于企业SaaS的解决方案和信息服务提供商，可提升医疗保健的质量和安全绩效。在此之前，他曾在2Wire、Solectron Corporation（NYSE：SLR）和安科投资（NYSE：SFE）担任执行财务和运营职务。他的职业生涯始于1993年，在Grant Thornton担任审计员，之后加入了普华永道会计师事务所的审计和商业咨询服务部门。Lakkaraju先生拥有圣何塞州立大学工商管理学士学位。
- Roop K. Lakkaraju has been Executive Vice President, Chief Financial Officer since January 2018. From February 2017 to January 2018 he served as Chief Financial Officer of Maana, Inc., an enterprise software company that has pioneered an Artificial Intelligence-driven knowledge platform. From October 2013 to February 2017 he served as Chief Operating Officer and Chief Financial Officer of Support.com NASDAQ:SPRT, a provider of cloud-based software and services for technology support. From July 2011 to October 2013 he was Chief Financial Officer of Quantros, Inc., a provider of enterprise SaaS-based solutions and information services that advance healthcare quality and safety performance. Prior to that he held executive financial and operational roles at 2Wire, Solectron Corporation (NYSE:SLR), and Safeguard Scientifics (NYSE:SFE). He began his career in 1993 as an auditor with Grant Thornton before joining PricewaterhouseCoopers in their Audit and Business Advisory Services. Mr. Lakkaraju holds a B.S. in Business Administration from San Jose State University.
- Allison Schwartz
Allison Schwartz，现任Bio-Rad Laboratories（加拿大）有限公司（子公司）商务总监，于2023年1月被任命担任该职务。在此之前，Schwartz女士于2021年7月至2023年1月担任Bio-Rad Laboratories（加拿大）有限公司的营销总监，之前于2016年至2021年担任Bio-Rad Laboratories的商务服务总监，负责全球数字营销、电子商务、客户体验和定价。自2005年加入Bio-Rad以来，她一直在国内外品牌开发、产品营销和物流管理方面担任职务。
Allison Schwartz,is currently the Commercial Director at Bio-Rad Laboratories (Canada) Limited (a subsidiary of the Company), a role to which she was appointed in January 2023. Prior to this assignment, Ms. Schwartz served as the Marketing Director at Bio-Rad Laboratories (Canada) Limited from July 2021 to January 2023, and previously as the Commercial Services Director at the Company from 2016 until 2021, with accountabilities in these roles spanning global digital marketing, eCommerce, customer experience, and pricing. Since joining Bio-Rad in 2005, she has held positions in domestic and international brand development, product marketing and logistics management.- Allison Schwartz，现任Bio-Rad Laboratories（加拿大）有限公司（子公司）商务总监，于2023年1月被任命担任该职务。在此之前，Schwartz女士于2021年7月至2023年1月担任Bio-Rad Laboratories（加拿大）有限公司的营销总监，之前于2016年至2021年担任Bio-Rad Laboratories的商务服务总监，负责全球数字营销、电子商务、客户体验和定价。自2005年加入Bio-Rad以来，她一直在国内外品牌开发、产品营销和物流管理方面担任职务。
- Allison Schwartz,is currently the Commercial Director at Bio-Rad Laboratories (Canada) Limited (a subsidiary of the Company), a role to which she was appointed in January 2023. Prior to this assignment, Ms. Schwartz served as the Marketing Director at Bio-Rad Laboratories (Canada) Limited from July 2021 to January 2023, and previously as the Commercial Services Director at the Company from 2016 until 2021, with accountabilities in these roles spanning global digital marketing, eCommerce, customer experience, and pricing. Since joining Bio-Rad in 2005, she has held positions in domestic and international brand development, product marketing and logistics management.
- Colleen Corey
Colleen Corey，于2019年8月被任命为全球人力资源执行副总裁。此前，她于2014年9月被任命为全球人力资源高级副总裁。在这一任命之前，自1996年加入Bio-Rad以来，Corey女士在人力资源领域担任了越来越多的职责。
Colleen Corey,was appointed Executive Vice President, Global Human Resources in August 2019. Previously, she was appointed Senior Vice President, Global Human Resources in September 2014. Prior to that appointment, Ms. Corey held various roles of increasing responsibility in Human Resources since joining Bio-Rad in 1996.- Colleen Corey，于2019年8月被任命为全球人力资源执行副总裁。此前，她于2014年9月被任命为全球人力资源高级副总裁。在这一任命之前，自1996年加入Bio-Rad以来，Corey女士在人力资源领域担任了越来越多的职责。
- Colleen Corey,was appointed Executive Vice President, Global Human Resources in August 2019. Previously, she was appointed Senior Vice President, Global Human Resources in September 2014. Prior to that appointment, Ms. Corey held various roles of increasing responsibility in Human Resources since joining Bio-Rad in 1996.
- Sedat Evran
Sedat Evran，于2023年9月被任命为全球供应链执行副总裁。在加入Bio-Rad之前，Evran先生于2020年至2023年在全球生命科学和诊断创新者丹纳赫公司担任全球运营和供应链副总裁，并于2019年至2020年担任运营和供应链种子副总裁。在此之前，他曾于2015年至2019年在全球分析服务和解决方案提供商Perkin Elmer担任诊断全球运营副总裁。Evran先生于2011年至2015年在Hil-Rom担任供应链领导职务，并于2001年至2011年在GE Healthcare和通用电气医疗系统担任供应链领导职务。
Sedat Evran,was appointed Executive Vice President, Global Supply Chain in September 2023. Prior to joining Bio-Rad, Mr. Evran was Vice President, Global Operations and Supply Chain at Danaher Corporation, a global life sciences and diagnostics innovator, from 2020 to 2023, and Vice President, Operations and Supply Chain Seed from 2019 to 2020. Prior to that, he was Vice President, Diagnostics Global Operations at Perkin Elmer, a global analytical services and solutions provider, from 2015 to 2019. Mr. Evran held supply chain leadership roles at Hil-Rom from 2011 to 2015, and at GE Healthcare and General Electric Medical Systems from 2001 to 2011.- Sedat Evran，于2023年9月被任命为全球供应链执行副总裁。在加入Bio-Rad之前，Evran先生于2020年至2023年在全球生命科学和诊断创新者丹纳赫公司担任全球运营和供应链副总裁，并于2019年至2020年担任运营和供应链种子副总裁。在此之前，他曾于2015年至2019年在全球分析服务和解决方案提供商Perkin Elmer担任诊断全球运营副总裁。Evran先生于2011年至2015年在Hil-Rom担任供应链领导职务，并于2001年至2011年在GE Healthcare和通用电气医疗系统担任供应链领导职务。
- Sedat Evran,was appointed Executive Vice President, Global Supply Chain in September 2023. Prior to joining Bio-Rad, Mr. Evran was Vice President, Global Operations and Supply Chain at Danaher Corporation, a global life sciences and diagnostics innovator, from 2020 to 2023, and Vice President, Operations and Supply Chain Seed from 2019 to 2020. Prior to that, he was Vice President, Diagnostics Global Operations at Perkin Elmer, a global analytical services and solutions provider, from 2015 to 2019. Mr. Evran held supply chain leadership roles at Hil-Rom from 2011 to 2015, and at GE Healthcare and General Electric Medical Systems from 2001 to 2011.
- Jonathan P. DiVincenzo
Jonathan P. DiVincenzo，他一直担任Central Laboratories and International的执行副总裁兼总裁（2013年5月以来）。DiVincenzo先生自2017年8月以来一直在Labcorp工作，自2019年10月以来担任临床试验测试解决方案总裁，在此之前，自2017年8月以来担任Covance总经理高级副总裁。在DiVincenzo先生的领导下，Labcorp在美国和国外开设了新的解剖病理学设施，并在新加坡、中国和日本完成了解剖病理学、基因组学和微生物学实验室的扩建。此外，他还领导Labcorp在比利时梅赫伦的自动化试剂盒装配线和在中国苏州的新试剂盒生产工厂的建设。在加入Labcorp之前，他曾担任PerkinElmer（精密光学公司）的环境健康部门总裁。加入PerkinElmer之前，他曾担任多个领导职务，包括酶学总裁兼首席执行官，EMD Millipore生物科学部总裁（Merk KGaA的子公司）。他持有Northeastern University的机械工程学士学位。
Jonathan P. DiVincenzo,has served as Executive Vice President and President, Central Laboratories and International since May 2023. Mr. DiVincenzo has been with Labcorp since August 2017, serving as President, Clinical Trials Testing Solutions since October 2019, and prior to that, as Senior Vice President, GM, Covance, since August 2017. Under Mr. DiVincenzo's leadership, Labcorp opened new anatomic pathology facilities in the United States and abroad and completed the expansion of anatomic pathology, genomics and microbiology labs in Singapore, China, and Japan. In addition, Mr. DiVincenzo led Labcorp's efforts to automate its kit assembly line in Mechelen, Belgium and the construction of a new kit production facility in Suzhou, China. Before joining Labcorp, he served as President of the Environmental Health division of PerkinElmer, a precision optics corporation. Prior to PerkinElmer, he has held numerous leadership roles, including President and Chief Executive Officer at Enzymatics and President of the Bioscience Division of EMD Millipore, a subsidiary of Merk KGaA. Mr. DiVincenzo holds a Bachelor's degree in Mechanical Engineering from Northeastern University.- Jonathan P. DiVincenzo，他一直担任Central Laboratories and International的执行副总裁兼总裁（2013年5月以来）。DiVincenzo先生自2017年8月以来一直在Labcorp工作，自2019年10月以来担任临床试验测试解决方案总裁，在此之前，自2017年8月以来担任Covance总经理高级副总裁。在DiVincenzo先生的领导下，Labcorp在美国和国外开设了新的解剖病理学设施，并在新加坡、中国和日本完成了解剖病理学、基因组学和微生物学实验室的扩建。此外，他还领导Labcorp在比利时梅赫伦的自动化试剂盒装配线和在中国苏州的新试剂盒生产工厂的建设。在加入Labcorp之前，他曾担任PerkinElmer（精密光学公司）的环境健康部门总裁。加入PerkinElmer之前，他曾担任多个领导职务，包括酶学总裁兼首席执行官，EMD Millipore生物科学部总裁（Merk KGaA的子公司）。他持有Northeastern University的机械工程学士学位。
- Jonathan P. DiVincenzo,has served as Executive Vice President and President, Central Laboratories and International since May 2023. Mr. DiVincenzo has been with Labcorp since August 2017, serving as President, Clinical Trials Testing Solutions since October 2019, and prior to that, as Senior Vice President, GM, Covance, since August 2017. Under Mr. DiVincenzo's leadership, Labcorp opened new anatomic pathology facilities in the United States and abroad and completed the expansion of anatomic pathology, genomics and microbiology labs in Singapore, China, and Japan. In addition, Mr. DiVincenzo led Labcorp's efforts to automate its kit assembly line in Mechelen, Belgium and the construction of a new kit production facility in Suzhou, China. Before joining Labcorp, he served as President of the Environmental Health division of PerkinElmer, a precision optics corporation. Prior to PerkinElmer, he has held numerous leadership roles, including President and Chief Executive Officer at Enzymatics and President of the Bioscience Division of EMD Millipore, a subsidiary of Merk KGaA. Mr. DiVincenzo holds a Bachelor's degree in Mechanical Engineering from Northeastern University.
- James J. Barry
James J. Barry，在过去的两年里，James Barry一直负责Bio-Rad的全球制造业务，包括质量、规划和整个组织的持续改进计划。在担任Global Manufacturing的职务之前，他负责监管Bio-Rad的质量系统部门，该部门为全球医院和参考实验室提供第三方独立质量控制材料和数据管理软件。Barry先生于2017年从贝克曼库尔特加入Bio-Rad，在那里他领导了实验室自动化和基因组学产品组合的销售，面向学术、制药和政府客户。他拥有罗斯豪曼理工学院机械工程学士学位和Pepperdine UniversityMBA学位。
James J. Barry,For the past two years, James Barry has been responsible for Bio-Rad's global manufacturing operations including quality, planning, and continuous improvement initiatives across the organization. Prior to his role within Global Manufacturing, he oversaw Bio-Rad's Quality Systems Division, which provides third-party independent quality control materials and data management software for hospitals and reference labs globally. Mr. Barry joined Bio-Rad in 2017 from Beckman Coulter where he led sales of the lab automation and genomics portfolio to academic, pharmaceutical, and government customers. He holds a B.S. degree in Mechanical Engineering from Rose Hulman Institute of Technology and an MBA from Pepperdine University.- James J. Barry，在过去的两年里，James Barry一直负责Bio-Rad的全球制造业务，包括质量、规划和整个组织的持续改进计划。在担任Global Manufacturing的职务之前，他负责监管Bio-Rad的质量系统部门，该部门为全球医院和参考实验室提供第三方独立质量控制材料和数据管理软件。Barry先生于2017年从贝克曼库尔特加入Bio-Rad，在那里他领导了实验室自动化和基因组学产品组合的销售，面向学术、制药和政府客户。他拥有罗斯豪曼理工学院机械工程学士学位和Pepperdine UniversityMBA学位。
- James J. Barry,For the past two years, James Barry has been responsible for Bio-Rad's global manufacturing operations including quality, planning, and continuous improvement initiatives across the organization. Prior to his role within Global Manufacturing, he oversaw Bio-Rad's Quality Systems Division, which provides third-party independent quality control materials and data management software for hospitals and reference labs globally. Mr. Barry joined Bio-Rad in 2017 from Beckman Coulter where he led sales of the lab automation and genomics portfolio to academic, pharmaceutical, and government customers. He holds a B.S. degree in Mechanical Engineering from Rose Hulman Institute of Technology and an MBA from Pepperdine University.
- Rajat Mehta
拉贾特·梅塔（Rajat Mehta）担任高级副总裁，负责监督该公司西部部门的大型商业运营。在加入徕博科之前，Mehta是赛默飞世尔的副总裁兼应用技术总经理。在这个职位上，他成功地管理了一个服务于不同市场的全球业务部门。在他职业生涯的早期，梅塔在陶氏化学担任越来越重要的商业角色，在那里他设计并执行了有影响力的商业增长战略。他拥有宾夕法尼亚大学沃顿商学院MBA学位和印度Thanesar的Kurkshetra大学电气工程学士学位。
Rajat Mehta,served as Senior Vice President, overseeing large-scale commercial operations for the company's West Division. Prior to Labcorp, Mehta was Vice President and General Manager, Applied Technologies, at Thermo Fisher Scientific. In this role, he successfully managed a global business unit serving diverse markets. Earlier in his career, Mehta held commercial roles of increasing responsibility at Dow Chemical, where he designed and executed impactful commercial growth strategies. He holds an MBA from The Wharton School at the University of Pennsylvania and a BS in Electrical Engineering from Kurkshetra University in Thanesar, India.- 拉贾特·梅塔（Rajat Mehta）担任高级副总裁，负责监督该公司西部部门的大型商业运营。在加入徕博科之前，Mehta是赛默飞世尔的副总裁兼应用技术总经理。在这个职位上，他成功地管理了一个服务于不同市场的全球业务部门。在他职业生涯的早期，梅塔在陶氏化学担任越来越重要的商业角色，在那里他设计并执行了有影响力的商业增长战略。他拥有宾夕法尼亚大学沃顿商学院MBA学位和印度Thanesar的Kurkshetra大学电气工程学士学位。
- Rajat Mehta,served as Senior Vice President, overseeing large-scale commercial operations for the company's West Division. Prior to Labcorp, Mehta was Vice President and General Manager, Applied Technologies, at Thermo Fisher Scientific. In this role, he successfully managed a global business unit serving diverse markets. Earlier in his career, Mehta held commercial roles of increasing responsibility at Dow Chemical, where he designed and executed impactful commercial growth strategies. He holds an MBA from The Wharton School at the University of Pennsylvania and a BS in Electrical Engineering from Kurkshetra University in Thanesar, India.
- Eva Anette Engelhardt
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Courtney Camp Enloe
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Norman Schwartz
Norman Schwartz，2003年开始担任Bio-Rad Laboratories, Inc.总裁兼首席执行官，2012年成为董事会主席。1989年到2002年，他是Bio-Rad Laboratories, Inc.副总裁，1997年到2002年，他是Life Science集团经理。1993年到1997年，他是Clinical Diagnostics公司团队经理。
Norman Schwartz,has been Bio-Rad Laboratories, Inc. President and Chief Executive Officer since 2003 and Bio-Rad Laboratories, Inc. Chairman of the Board since 2012. He was Bio-Rad Laboratories, Inc. Vice President from 1989 to 2002, Bio-Rad Laboratories, Inc. Group Manager, Life Science, from 1997 to 2002 and Bio-Rad Laboratories, Inc. Group Manager, Clinical Diagnostics, from 1993 to 1997.- Norman Schwartz，2003年开始担任Bio-Rad Laboratories, Inc.总裁兼首席执行官，2012年成为董事会主席。1989年到2002年，他是Bio-Rad Laboratories, Inc.副总裁，1997年到2002年，他是Life Science集团经理。1993年到1997年，他是Clinical Diagnostics公司团队经理。
- Norman Schwartz,has been Bio-Rad Laboratories, Inc. President and Chief Executive Officer since 2003 and Bio-Rad Laboratories, Inc. Chairman of the Board since 2012. He was Bio-Rad Laboratories, Inc. Vice President from 1989 to 2002, Bio-Rad Laboratories, Inc. Group Manager, Life Science, from 1997 to 2002 and Bio-Rad Laboratories, Inc. Group Manager, Clinical Diagnostics, from 1993 to 1997.